US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
SDEV
$7.48
▲+0.00%
WDC
$415.29
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
SDEV
$7.48
▲+0.00%
WDC
$415.29
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Corstasis Therapeutics Inc.
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
March 03, 2026
From
Corstasis Therapeutics Inc.
Via
Business Wire
Tickers
ESPR
Corstasis Therapeutics and Cardiovascular Logistics Partner to Redefine Outpatient Heart Failure Care with ENBUMYST™ (Bumetanide Nasal Spray)
November 26, 2025
From
Corstasis Therapeutics Inc.
Via
Business Wire
Corstasis Therapeutics and U.S. Heart and Vascular® Collaboration Will Seek to Improve Heart Failure Care with ENBUMYST™ (Bumetanide Nasal Spray)
September 25, 2025
From
Corstasis Therapeutics Inc.
Via
Business Wire
Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
September 15, 2025
From
Corstasis Therapeutics Inc.
Via
Business Wire
Corstasis Therapeutics Strenghtens Leadership Team with the Appointment of Dr. Amin Medjamia as VP of Medical Affairs
September 11, 2025
From
Corstasis Therapeutics Inc.
Via
Business Wire
Corstasis Therapeutics Announces Allowance of a New Patent and Development Updates for Subcutaneous Programs RSQ-786 and RSQ-789
September 03, 2025
From
Corstasis Therapeutics Inc.
Via
Business Wire
Corstasis Therapeutics Announces Appointment of Sanjeev Narula to its Strategic Advisory Board
July 23, 2025
From
Corstasis Therapeutics Inc.
Via
Business Wire
Corstasis Therapeutics Inc. Announces FDA Acceptance of New Drug Application for Bumetanide Nasal Spray
January 27, 2025
From
Corstasis Therapeutics Inc.
Via
Business Wire
Corstasis Therapeutics to Present Pivotal Trial Data on Novel Bumetanide Nasal Spray at American Heart Association Scientific Sessions 2024
November 15, 2024
From
Corstasis Therapeutics Inc.
Via
Business Wire
